P2.14-02. TP53 Mutations Affect Sensitivity to Lorlatinib in ROS1 Positive NSCLC: Final Results of the PFROST Trial
Back to course
Pdf Summary
Asset Subtitle
Lorenza Landi, Italy
Meta Tag
Speaker Lorenza Landi, Italy
Topic Tumour Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics
PFROST trial
ROS1 non-small-cell lung cancer
overall response rate
progression-free survival
overall survival
baseline brain metastases
TP53 gene mutations
personalized treatment approaches
Powered By